4.8 Review

Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease

期刊

NATURE REVIEWS DRUG DISCOVERY
卷 15, 期 9, 页码 620-638

出版社

NATURE PORTFOLIO
DOI: 10.1038/nrd.2016.89

关键词

-

资金

  1. US National Institutes of Health
  2. Center for Innovative Technology
  3. Virginia Biosciences Health Research Corporation
  4. LOEWE Center for Cell and Gene Therapy (State of Hesse)
  5. Excellence Cluster Cardio-Pulmonary System (ECCPS)
  6. Excellence Cluster Cardio-Pulmonary System (Deutsche Forschungsgemeinschaft [Exc147-2]
  7. Leducq Network Minimal Invasive Right Ventricular Assist Device (MIRVAD) project
  8. European Research Council
  9. British Heart Foundation
  10. British Heart Foundation [FS/12/17/29532] Funding Source: researchfish

向作者/读者索取更多资源

Our understanding of the functions of cardiac fibroblasts has moved beyond their roles in heart structure and extracellular matrix generation and now includes their contributions to paracrine, mechanical and electrical signalling during ontogenesis and normal cardiac activity. Fibroblasts also have central roles in pathogenic remodelling during myocardial ischaemia, hypertension and heart failure. As key contributors to scar formation, they are crucial for tissue repair after interventions including surgery and ablation. Novel experimental approaches targeting cardiac fibroblasts are promising potential therapies for heart disease. Indeed, several existing drugs act, at least partially, through effects on cardiac connective tissue. This Review outlines the origins and roles of fibroblasts in cardiac development, homeostasis and disease; illustrates the involvement of fibroblasts in current and emerging clinical interventions; and identifies future targets for research and development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据